A phase II clinical study of 13-deoxy, 5-iminodoxorubicin (GPX-150) with metastatic and unresectable soft tissue sarcoma.

Brian Andrew Van TineMark AgulnikRichard D OlsonGerald M WalshArthur KlausnerNicole E FrankTodd T TalleyMohammed M Milhem

Published in: Cancer medicine (2019)

These results suggest future studies are warranted to further evaluate the clinical efficacy of GPX-150 in STS, perhaps at doses higher than 265 mg/m2 .

Keyphrases

phase ii
clinical trial
open label
double blind
squamous cell carcinoma
placebo controlled
small cell lung cancer
locally advanced
current status
phase iii
case control
liver metastases
radiation therapy
randomized controlled trial